Consistent with the outcomes of the combination regimen in the KHM‐5M xenografts, we observed that xenograft tumor growth was significantly suppressed in the combination treatment group of lenvatinib and CDK2 inhibitor compared with the monotherapy group or the vehicle group for the PDX10, PDX12 and PDX13 (Figure 7c–e; Figure S6a,c–e, Supporting Information). The gene discussed is CDK2; the disease is neoplasm.